Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

DermBiont axed trials of its original lead dermatology gel, the biotech confirmed to Endpoints News, and with little investor appetite for microbiome-based therapies, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of Se­ries B

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B